J&J Files Antitrust Complaint Against Amgen For Aranesp Pricing Practice
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's bundling of rebates for Aranesp, Neulasta and Neupogen have unfairly increased the anemia therapy's market share, the complaint alleges.